Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

GRFS

Grifols (GRFS)

Grifols SA
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:GRFS
일자시간출처헤드라인심볼기업
2024/04/2005:42PR Newswire (US)Grifols 2023 Annual Report on Form 20-F filed with the SECNASDAQ:GRFSGrifols SA
2024/04/1822:30GlobeNewswire Inc.Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.NASDAQ:GRFSGrifols SA
2024/04/1520:06IH Market NewsSamsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More NewsNASDAQ:GRFSGrifols SA
2024/04/0417:00GlobeNewswire Inc.Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus ScreeningNASDAQ:GRFSGrifols SA
2024/03/2222:07IH Market NewsFedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest NewsNASDAQ:GRFSGrifols SA
2024/03/0820:19IH Market NewsCNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest NewsNASDAQ:GRFSGrifols SA
2024/02/1417:16GlobeNewswire Inc.Grifols announces positive topline phase 3 fibrinogen clinical trial resultsNASDAQ:GRFSGrifols SA
2024/01/2707:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2024/01/1620:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2024/01/1220:10IH Market NewsWall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and MoreNASDAQ:GRFSGrifols SA
2024/01/1103:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2024/01/1022:59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2024/01/1020:21IH Market NewsWall Street Highlights: Tesla Launches Restyled Model 3, VinFast Unveils Pickup Prototype, and MoreNASDAQ:GRFSGrifols SA
2024/01/1004:49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2024/01/0922:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2023/12/2923:59Dow Jones NewsGrifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down DebtNASDAQ:GRFSGrifols SA
2023/12/2923:46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2023/12/2923:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2023/11/1619:00PR Newswire (US)Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patientsNASDAQ:GRFSGrifols SA
2023/11/1522:00GlobeNewswire Inc.Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin DeficiencyNASDAQ:GRFSGrifols SA
2023/11/0622:00GlobeNewswire Inc.GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023NASDAQ:GRFSGrifols SA
2023/11/0302:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2023/10/2507:30GlobeNewswire Inc.Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTADNASDAQ:GRFSGrifols SA
2023/10/2021:36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2023/10/1921:00GlobeNewswire Inc.GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum NeurotoxinsNASDAQ:GRFSGrifols SA
2023/09/2821:00GlobeNewswire Inc.GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564NASDAQ:GRFSGrifols SA
2023/08/0121:00GlobeNewswire Inc.Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and AnalyticsNASDAQ:GRFSGrifols SA
2023/07/2800:44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
2023/07/2021:15GlobeNewswire Inc.Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for PatientsNASDAQ:GRFSGrifols SA
2023/07/1821:00GlobeNewswire Inc.Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated CirrhosisNASDAQ:GRFSGrifols SA
 검색 관련기사 보기:NASDAQ:GRFS